Reprogrammed cell delivery for personalized medicine

Advanced Drug Delivery Reviews

Volumn 64, Issue 13, 2012, Pages 1477-1487

  Wieland, Markus ^a   Fussenegger, Martin ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

Gene circuit; Genetic switch; Microencapsulation; Prosthetic network; Synthetic biology

Indexed keywords

ARTIFICIAL INSEMINATION; BLOOD GLUCOSE; BLUE LIGHT; CANCER CELLS; CELL DELIVERY; CELL-BASED; COST-INTENSIVE; GENE CIRCUITS; GENETIC BACKGROUNDS; HORMONE LEVELS; METABOLIC PARAMETERS; MICROENCAPSULATION; PERSONALIZED MEDICINES; POST-TRANSCRIPTIONAL; PRODUCTION FACILITY; SYNTHETIC BIOLOGY;

BLOOD; CELL PROLIFERATION; CELLS; DRUG DELIVERY; GENES; GLUCOSE; PHYSIOLOGY; RESTORATION; SWITCHING CIRCUITS;

CYTOLOGY;

BETA ENDORPHIN; CILIARY NEUROTROPHIC FACTOR; DOUBLE STRANDED RNA; GLUCAGON LIKE PEPTIDE 1; HAMMERHEAD RIBOZYME; INSULIN; INTERLEUKIN 2; LUTEINIZING HORMONE; RNA INDUCED SILENCING COMPLEX; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR; URATE; URATE OXIDASE;

ARTIFICIAL INSEMINATION; BIOSENSOR; BLUE LIGHT; CANCER DIAGNOSIS; CELL ENGINEERING; DRUG DELIVERY SYSTEM; GENE CONTROL; GENE SWITCHING; GLUCOSE HOMEOSTASIS; HUMAN; HUNTINGTON CHOREA; LYMPHOCYTE PROLIFERATION; MICROENCAPSULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PAIN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; RNA PROCESSING; SYNTHETIC BIOLOGY; TRANSCRIPTION REGULATION; URIC ACID BLOOD LEVEL;

ANIMALS; DRUG DELIVERY SYSTEMS; GENE REGULATORY NETWORKS; HUMANS; INDIVIDUALIZED MEDICINE; SYNTHETIC BIOLOGY;

EID: 84867644803     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2012.06.005     Document Type: Review

References (100)

1. Roberts R. Personalized medicine: a reality within this decade. J. Cardiovasc. Transl. 2008, 1:11-16.
2. Lam C.W., Lau K.C., Tong S.F. Microarrays for personalized genomic medicine. Adv. Clin. Chem. 2010, 52:1-18.
3. Chan I.S., Ginsburg G.S. Personalized medicine: progress and promise. Annu. Rev. Genomics Hum. Genet. 2011, 12:217-244.
4. Gossen M., Freundlieb S., Bender G., Muller G., Hillen W., Bujard H. Transcriptional activation by tetracyclines in mammalian cells. Science 1995, 268:1766-1769.
5. Gossen M., Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:5547-5551.
6. Tigges M., Marquez-Lago T.T., Stelling J., Fussenegger M. A tunable synthetic mammalian oscillator. Nature 2009, 457:309-312.
7. Nevins J.R. Transcriptional activation by viral regulatory proteins. Trends Biochem. Sci. 1991, 16:435-439.
8. Deuschle U., Meyer W.K., Thiesen H.J. Tetracycline-reversible silencing of eukaryotic promoters. Mol. Cell. Biol. 1995, 15:1907-1914.
9. Ryan R.F., Schultz D.C., Ayyanathan K., Singh P.B., Friedman J.R., Fredericks W.J., Rauscher F.J. KAP-1 corepressor protein interacts and colocalizes with heterochromatic and euchromatic HP1 proteins: a potential role for Kruppel-associated box-zinc finger proteins in heterochromatin-mediated gene silencing. Mol. Cell. Biol. 1999, 19:4366-4378.
10. Boch J., Scholze H., Schornack S., Landgraf A., Hahn S., Kay S., Lahaye T., Nickstadt A., Bonas U. Breaking the code of DNA binding specificity of TAL-type III effectors. Science 2009, 326:1509-1512.
11. Maeder M.L., Thibodeau-Beganny S., Osiak A., Wright D.A., Anthony R.M., Eichtinger M., Jiang T., Foley J.E., Winfrey R.J., Townsend J.A., Unger-Wallace E., Sander J.D., Muller-Lerch F., Fu F., Pearlberg J., Gobel C., Dassie J.P., Pruett-Miller S.M., Porteus M.H., Sgroi D.C., Iafrate A.J., Dobbs D., McCray P.B., Cathomen T., Voytas D.F., Joung J.K. Rapid "open-source" engineering of customized zinc-finger nucleases for highly efficient gene modification. Mol. Cell 2008, 31:294-301.
12. Moscou M.J., Bogdanove A.J. A simple cipher governs DNA recognition by TAL effectors. Science 2009, 326:1501.
13. Sander J.D., Dahlborg E.J., Goodwin M.J., Cade L., Zhang F., Cifuentes D., Curtin S.J., Blackburn J.S., Thibodeau-Beganny S., Qi Y., Pierick C.J., Hoffman E., Maeder M.L., Khayter C., Reyon D., Dobbs D., Langenau D.M., Stupar R.M., Giraldez A.J., Voytas D.F., Peterson R.T., Yeh J.R., Joung J.K. Selection-free zinc-finger-nuclease engineering by context-dependent assembly (CoDA). Nat. Methods 2011, 8:67-69.
14. Carroll D. Genome engineering with zinc-finger nucleases. Genetics 2011, 188:773-782.
15. Sanjana N.E., Cong L., Zhou Y., Cunniff M.M., Feng G., Zhang F. A transcription activator-like effector toolbox for genome engineering. Nat. Protoc. 2012, 7:171-192.
16. Ramos J.L., Martinez-Bueno M., Molina-Henares A.J., Teran W., Watanabe K., Zhang X., Gallegos M.T., Brennan R., Tobes R. The TetR family of transcriptional repressors. Microbiol. Mol. Biol. Rev. 2005, 69:326-356.
17. Mullick A., Xu Y., Warren R., Koutroumanis M., Guilbault C., Broussau S., Malenfant F., Bourget L., Lamoureux L., Lo R., Caron A.W., Pilotte A., Massie B. The cumate gene-switch: a system for regulated expression in mammalian cells. BMC Biotechnol. 2006, 6:43.
18. Weber W., Fux C., Daoud-el Baba M., Keller B., Weber C.C., Kramer B.P., Heinzen C., Aubel D., Bailey J.E., Fussenegger M. Macrolide-based transgene control in mammalian cells and mice. Nat. Biotechnol. 2002, 20:901-907.
19. Fussenegger M., Morris R.P., Fux C., Rimann M., von Stockar B., Thompson C.J., Bailey J.E. Streptogramin-based gene regulation systems for mammalian cells. Nat. Biotechnol. 2000, 18:1203-1208.
20. Weber W., Bacchus W., Gruber F., Hamberger M., Fussenegger M. A novel vector platform for vitamin H-inducible transgene expression in mammalian cells. J. Biotechnol. 2007, 131:150-158.
21. Hartenbach S., Daoud-El Baba M., Weber W., Fussenegger M. An engineered L-arginine sensor of Chlamydia pneumoniae enables arginine-adjustable transcription control in mammalian cells and mice. Nucleic Acids Res. 2007, 35:e136.
22. Weber W., Rimann M., Spielmann M., Keller B., Daoud-El Baba M., Aubel D., Weber C.C., Fussenegger M. Gas-inducible transgene expression in mammalian cells and mice. Nat. Biotechnol. 2004, 22:1440-1444.
23. Kole R., Krainer A.R., Altman S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat. Rev. Drug Discov. 2012, 11:125-140.
24. Perrimon N., Ni J.Q., Perkins L. In vivo RNAi: today and tomorrow. Cold Spring Harb. Perspect. Biol. 2010, 2:a003640.
25. Wieland M., Fussenegger M. Ligand-dependent regulatory RNA parts for synthetic biology in eukaryotes. Curr. Opin. Biotechnol. 2010, 21:760-765.
26. Weinstein S., Peer D. RNAi nanomedicines: challenges and opportunities within the immune system. Nanotechnology 2010, 21.
27. Macrae I.J., Zhou K., Li F., Repic A., Brooks A.N., Cande W.Z., Adams P.D., Doudna J.A. Structural basis for double-stranded RNA processing by Dicer. Science 2006, 311:195-198.
28. Kawamata T., Tomari Y. Making RISC. Trends Biochem. Sci. 2010, 35:368-376.
29. Agrawal N., Dasaradhi P.V., Mohmmed A., Malhotra P., Bhatnagar R.K., Mukherjee S.K. RNA interference: biology, mechanism, and applications. Microbiol. Mol. Biol. Rev. 2003, 67:657-685.
30. Sashital D.G., Doudna J.A. Structural insights into RNA interference. Curr. Opin. Struct. Biol. 2010, 20:90-97.
31. Dickins R.A., Hemann M.T., Zilfou J.T., Simpson D.R., Ibarra I., Hannon G.J., Lowe S.W. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat. Genet. 2005, 37:1289-1295.
32. Greber D., El-Baba M.D., Fussenegger M. Intronically encoded siRNAs improve dynamic range of mammalian gene regulation systems and toggle switch. Nucleic Acids Res. 2008, 36.
33. Malphettes L., Fussenegger M. Macrolide- and tetracycline-adjustable siRNA-mediated gene silencing in mammalian cells using polymerase II-dependent promoter derivatives. Biotechnol. Bioeng. 2004, 88:417-425.
34. Stegmeier F., Hu G., Rickles R.J., Hannon G.J., Elledge S.J. A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:13212-13217.
35. Famulok M., Mayer G. Aptamers as tools in molecular biology and immunology. Curr. Top. Microbiol. 1999, 243:123-136.
36. Green M.R., Werstuck G. Controlling gene expression in living cells through small molecule-RNA interactions. Science 1998, 282:296-298.
37. Saito H., Kobayashi T., Hara T., Fujita Y., Hayashi K., Furushima R., Inoue T. Synthetic translational regulation by an L7Ae-kink-turn RNP switch. Nat. Chem. Biol. 2010, 6:71-78.
38. Nelson J.A., Uhlenbeck O.C. Hammerhead redux: does the new structure fit the old biochemical data?. Rna-a Publication of the Rna Society 2008, 14:605-615.
39. Wieland M., Ausländer D., Fussenegger M. Engineering of ribozyme-based riboswitches for mammalian cells. Methods 2012, 56:351-357.
40. Yen L., Magnier M., Weissleder R., Stockwell B.R., Mulligan R.C. Identification of inhibitors of ribozyme self-cleavage in mammalian cells via high-throughput screening of chemical libraries. RNA 2006, 12:797-806.
41. Yen L., Svendsen J., Lee J.S., Gray J.T., Magnier M., Baba T., D'Amato R.J., Mulligan R.C. Exogenous control of mammalian gene expression through modulation of RNA self-cleavage. Nature 2004, 431:471-476.
42. Chen Y.Y., Jensen M.C., Smolke C.D. Genetic control of mammalian T-cell proliferation with synthetic RNA regulatory systems. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:8531-8536.
43. Smolke C.D., Win M.N. Higher-order cellular information processing with synthetic RNA devices. Science 2008, 322:456-460.
44. Auslander S., Ketzer P., Hartig J.S. A ligand-dependent hammerhead ribozyme switch for controlling mammalian gene expression. Mol. Biosyst. 2010, 6:807-814.
45. An C.I., Trinh V.B., Yokobayashi Y. Artificial control of gene expression in mammalian cells by modulating RNA interference through aptamer-small molecule interaction. RNA 2006, 12:710-716.
46. Beisel C.L., Chen Y.Y., Culler S.J., Hoff K.G., Smolke C.D. Design of small molecule-responsive microRNAs based on structural requirements for Drosha processing. Nucleic Acids Res. 2011, 39:2981-2994.
47. Saito H., Fujita Y., Kashida S., Hayashi K., Inoue T. Synthetic human cell fate regulation by protein-driven RNA switches. Nat. Commun. 2011, 2:160.
48. Vilardaga J.P., Bunemann M., Feinstein T.N., Lambert N., Nikolaev V.O., Engelhardt S., Lohse M.J., Hoffmann C. GPCR and G proteins: drug efficacy and activation in live cells. Mol. Endocrinol. 2009, 23:590-599.
49. Ye R.D. Regulation of nuclear factor kappaB activation by G-protein-coupled receptors. J. Leukoc. Biol. 2001, 70:839-848.
50. Marinissen M.J., Gutkind J.S. G-protein-coupled receptors and signaling networks: emerging paradigms. Trends Pharmacol. Sci. 2001, 22:368-376.
51. Ho M.K., Su Y., Yeung W.W., Wong Y.H. Regulation of transcription factors by heterotrimeric G proteins. Curr. Mol. Pharmacol. 2009, 2:19-31.
52. Durocher Y., Perret S., Thibaudeau E., Gaumond M.H., Kamen A., Stocco R., Abramovitz M. A reporter gene assay for high-throughput screening of G-protein-coupled receptors stably or transiently expressed in HEK293 EBNA cells grown in suspension culture. Anal. Biochem. 2000, 284:316-326.
53. Kemmer C., Fluri D.A., Witschi U., Passeraub A., Gutzwiller A., Fussenegger M. A designer network coordinating bovine artificial insemination by ovulation-triggered release of implanted sperms. J. Control. Release 2011, 150:23-29.
54. Ye H., Daoud-El Baba M., Peng R.W., Fussenegger M. A synthetic optogenetic transcription device enhances blood-glucose homeostasis in mice. Science 2011, 332:1565-1568.
55. Wang Y., Cheong C.G., Hall T.M., Wang Z. Engineering splicing factors with designed specificities. Nat. Methods 2009, 6:825-830.
56. Culler S.J., Hoff K.G., Smolke C.D. Reprogramming cellular behavior with RNA controllers responsive to endogenous proteins. Science 2010, 330:1251-1255.
57. Xie Z., Wroblewska L., Prochazka L., Weiss R., Benenson Y. Multi-input RNAi-based logic circuit for identification of specific cancer cells. Science 2011, 333:1307-1311.
58. Nissim L., Bar-Ziv R.H. A tunable dual-promoter integrator for targeting of cancer cells. Mol. Syst. Biol. 2010, 6:444.
59. Nettelbeck D.M. Cellular genetic tools to control oncolytic adenoviruses for virotherapy of cancer. J. Mol. Med. (Berl) 2008, 86:363-377.
60. Dorer D.E., Nettelbeck D.M. Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis. Adv. Drug Deliv. Rev. 2009, 61:554-571.
61. Barak Y., Handelsman T., Nakar D., Mechaly A., Lamed R., Shoham Y., Bayer E.A. Matching fusion protein systems for affinity analysis of two interacting families of proteins: the cohesin-dockerin interaction. J. Mol. Recognit. 2005, 18:491-501.
62. Brase J.C., Wuttig D., Kuner R., Sultmann H. Serum microRNAs as non-invasive biomarkers for cancer. Mol. Cancer 2010, 9.
63. Jenison R.D., Gill S.C., Pardi A., Polisky B. High-resolution molecular discrimination by RNA. Science 1994, 263:1425-1429.
64. Shimizu A., Kondo S., Sabe H., Ishida N., Honjo T. Structure and function of the interleukin-2 receptor-affinity conversion model. Immunol. Rev. 1986, 92:103-120.
65. Hunder N.N., Wallen H., Cao J., Hendricks D.W., Reilly J.Z., Rodmyre R., Jungbluth A., Gnjatic S., Thompson J.A., Yee C. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N. Engl. J. Med. 2008, 358:2698-2703.
66. Morgan R.A., Dudley M.E., Wunderlich J.R., Hughes M.S., Yang J.C., Sherry R.M., Royal R.E., Topalian S.L., Kammula U.S., Restifo N.P., Zheng Z., Nahvi A., de Vries C.R., Rogers-Freezer L.J., Mavroukakis S.A., Rosenberg S.A. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006, 314:126-129.
67. Zhang H., Zhu S.J., Wang W., Wei Y.J., Hu S.S. Transplantation of microencapsulated genetically modified xenogeneic cells augments angiogenesis and improves heart function. Gene Ther. 2008, 15:40-48.
68. Lim F., Sun A.M. Microencapsulated islets as bioartificial endocrine pancreas. Science 1980, 210:908-910.
69. Dubrot J., Portero A., Orive G., Hernandez R.M., Palazon A., Rouzaut A., Perez-Gracia J.L., Hervas-Stubbs S., Pedraz J.L., Melero I. Delivery of immunostimulatory monoclonal antibodies by encapsulated hybridoma cells. Cancer Immunol. Immunother. 2010, 59:1621-1631.
70. Wang W., Liu X.D., Xie Y.B., Zhang H., Yu W.T., Xiong Y., Xie W.Y., Ma X.J. Microencapsulation using natural polysaccharides for drug delivery and cell implantation. J. Mater. Chem. 2006, 16:3252-3267.
71. Drury J.L., Mooney D.J. Hydrogels for tissue engineering: scaffold design variables and applications. Biomaterials 2003, 24:4337-4351.
72. Hernandez R.M., Orive G., Murua A., Pedraz J.L. Microcapsules and microcarriers for in situ cell delivery. Adv. Drug Deliv. Rev. 2010, 62:711-730.
73. Koo J., Chang T.M.S. Secretion of erythropoietin from microencapsulated rat-kidney cells-preliminary-results. Int. J. Artif. Organs 1993, 16:557-560.
74. Wong H., Chang T.M.S. Bioartificial liver-implanted artificial cells microencapsulated living hepatocytes increases survival of liver-failure rats. Int. J. Artif. Organs 1986, 9:335-336.
75. Saitoh Y., Taki T., Arita N., Ohnishi T., Hayakawa T. Cell therapy with encapsulated xenogeneic tumor-cells secreting beta-endorphin for treatment of peripheral pain. Cell Transplant. 1995, 4:S13-S17.
76. Bachoud-Levi A.C., Deglon N., Nguyen J.P., Bloch J., Bourdet C., Winkel L., Remy P., Goddard M., Lefaucheur J.P., Brugieres P., Baudic S., Cesaro P., Peschanski M., Aebischer P. Neuroprotective gene therapy for Huntington's disease using a polymer encapsulated BHK cell line engineered to secrete human CNTF. Hum. Gene Ther. 2000, 11:1723-1729.
77. Bloch J., Bachoud-Levi A.C., Deglon N., Lefaucheur J.P., Winkel L., Palfi S., Nguyen J.P., Bourdet C., Gaura V., Remy P., Brugieres P., Boisse M.F., Baudic S., Cesaro P., Hantraye P., Aebischer P., Peschanski M. Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study. Hum. Gene Ther. 2004, 15:968-975.
78. Kobayashi K., Yasuhara T., Agari T., Muraoka K., Kameda M., Ji Yuan W., Hayase H., Matsui T., Miyoshi Y., Shingo T., Date I. Control of dopamine-secretion by Tet-Off system in an in vivo model of parkinsonian rat. Brain Res. 2006, 1102:1-11.
79. Ma Y., Feigin A., Dhawan V., Fukuda M., Shi Q., Greene P., Breeze R., Fahn S., Freed C., Eidelberg D. Dyskinesia after fetal cell transplantation for parkinsonism: a PET study. Ann. Neurol. 2002, 52:628-634.
80. Weber W., Schoenmakers R., Keller B., Gitzinger M., Grau T., Daoud-El Baba M., Sander P., Fussenegger M. A synthetic mammalian gene circuit reveals antituberculosis compounds. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:9994-9998.
81. Gitzinger M., Kemmer C., El-Baba M.D., Weber W., Fussenegger M. Controlling transgene expression in subcutaneous implants using a skin lotion containing the apple metabolite phloretin. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:10638-10643.
82. Gitzinger M., Kemmer C., Fluri D.A., Daoud El-Baba M., Weber W., Fussenegger M. The food additive vanillic acid controls transgene expression in mammalian cells and mice. Nucleic Acids Res. 2012, 40:e37.
83. Giannini C., Mohn A., Chiarelli F. Technology and the issue of cost/benefit in diabetes. Diabetes Metab. Res. Rev. 2009, 25(Suppl. 1):S34-S44.
84. Vigersky R.A. An overview of management issues in adult patients with type 2 diabetes mellitus. J. Diabetes Sci. Technol. 2011, 5:245-250.
85. Sanz C., Gautier J.F., Hanaire H. Physical exercise for the prevention and treatment of type 2 diabetes. Diabetes Metab. 2010, 36:346-351.
86. Siram A.T., Yanagisawa R., Skamagas M. Weight management in type 2 diabetes mellitus. Mt. Sinai J. Med. 2010, 77:533-548.
87. Parsons G.B., Souza D.W., Wu H., Yu D., Wadsworth S.G., Gregory R.J., Armentano D. Ectopic expression of glucagon-like peptide 1 for gene therapy of type II diabetes. Gene Ther. 2007, 14:38-48.
88. Walker M.T., Brown R.L., Cronin T.W., Robinson P.R. Photochemistry of retinal chromophore in mouse melanopsin. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:8861-8865.
89. Panda S., Nayak S.K., Campo B., Walker J.R., Hogenesch J.B., Jegla T. Illumination of the melanopsin signaling pathway. Science 2005, 307:600-604.
90. Kemmer C., Gitzinger M., Daoud-El Baba M., Djonov V., Stelling J., Fussenegger M. Self-sufficient control of urate homeostasis in mice by a synthetic circuit. Nat. Biotechnol. 2010, 28:355-360.
91. Legoux R., Delpech B., Dumont X., Guillemot J.C., Ramond P., Shire D., Caput D., Ferrara P., Loison G. Cloning and expression in Escherichia coli of the gene encoding Aspergillus flavus urate oxidase. J. Biol. Chem. 1992, 267:8565-8570.
92. Cameron M.A., Sakhaee K. Uric acid nephrolithiasis. Urol. Clin. North Am. 2007, 34:335-346.
93. Kutzing M.K., Firestein B.L. Altered uric acid levels and disease states. J. Pharmacol. Exp. Ther. 2008, 324:1-7.
94. Wilkinson S.P., Grove A. HucR, a novel uric acid-responsive member of the MarR family of transcriptional regulators from Deinococcus radiodurans. J. Biol. Chem. 2004, 279:51442-51450.
95. Endou H., Enomoto A., Kimura H., Chairoungdua A., Shigeta Y., Jutabha P., Cha S.H., Hosoyamada M., Takeda M., Sekine T., Igarashi T., Matsuo H., Kikuchi Y., Oda T., Ichida K., Hosoya T., Shimokata K., Niwa T., Kanai Y. Molecular identification of a renal urate-anion exchanger that regulates blood urate levels. Nature 2002, 417:447-452.
96. Faustini M., Riccardi A., Villani S., Russo V., Torre M.L., Conte U., Vigo D. A single insemination intervention in the sow with barium alginate-encapsulated boar semen. Vet. Res. Commun. 2008, 32(Suppl. 1):S147-S149.
97. Faustini M., Torre M.L., Stacchezzini S., Norberti R., Consiglio A.L., Porcelli F., Conte U., Munari E., Russo V., Vigo D. Boar spermatozoa encapsulated in barium alginate membranes: a microdensitometric evaluation of some enzymatic activities during storage at 18 degrees C. Theriogenology 2004, 61:173-184.
98. Fluri D.A., Kemmer C., Daoud-El Baba M., Fussenegger M. A novel system for trigger-controlled drug release from polymer capsules. J. Control. Release 2008, 131:211-219.
99. Ascoli M., Fanelli F., Segaloff D.L. The lutropin/choriogonadotropin receptor, a 2002 perspective. Endocr. Rev. 2002, 23:141-174.
100. Porter D.L., Levine B.L., Kalos M., Bagg A., June C.H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 2011, 365:725-733.